{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:37:26Z","timestamp":1793320646196,"version":"4.5.0"},"reference-count":228,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["52273128"],"award-info":[{"award-number":["52273128"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2022A1515220048"],"award-info":[{"award-number":["2022A1515220048"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Guangdong Provincial Key Laboratory of Tumor Interventional Diagnosis and Treatment"},{"name":"Zhuhai High Level Health Team Flexible Project"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Targeted therapy has revolutionized the treatment landscape of hepatocellular carcinoma (HCC), offering unprecedented hope to patients. However, despite its promise, significant challenges arise in the form of drug resistance. Only a fraction of HCC patients respond to targeted therapy, and even those who respond often develop resistance over time. Sorafenib and lenvatinib, the sole first-line targeted therapeutic drugs for HCC, face severe clinical limitations due to drug resistance. Understanding the mechanisms underlying sorafenib\/lenvatinib resistance is crucial for maximizing treatment efficacy. Recent studies have highlighted the pivotal role of epigenetic regulation in drug resistance. Cancer is recognized as both a genetic and epigenetic disease, with epigenetic factors influencing various aspects of tumor cell biology, especially drug resistance. This review systematically summarizes the mechanisms of epigenetic-mediated sorafenib\/lenvatinib resistance, encompassing non-coding RNA (ncRNA) regulation, DNA methylation, RNA methylation, and histone modification. These abnormal epigenetic processes typically influence biological activities, including escaped programmed cell death, tumor metabolic reprogramming, formation and maintenance of drug-resistant cells, uncontrolled cell proliferation signaling pathways, and abnormal transport processes, ultimately culminating in profound drug resistance. By comprehensively summarizing the latest discoveries in epigenetic regulation mechanisms, this review highlights potential strategies to overcome drug resistance, paving the way for future advancements in HCC treatment.<\/jats:p>","DOI":"10.1038\/s41419-025-08105-x","type":"journal-article","created":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T07:36:26Z","timestamp":1764142586000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Resistance of first-line targeted drugs in hepatocellular carcinoma: the epigenetic regulation mechanisms"],"prefix":"10.1038","volume":"16","author":[{"given":"Ding","family":"Qi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongqing","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haidong","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0567-5149","authenticated-orcid":false,"given":"Yong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6769-5810","authenticated-orcid":false,"given":"Shisong","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,26]]},"reference":[{"key":"8105_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"8105_CR2","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.gendis.2020.01.014","volume":"7","author":"W Wang","year":"2020","unstructured":"Wang W, Wei C. Advances in the early diagnosis of hepatocellular carcinoma. Genes Dis. 2020;7:308\u201319.","journal-title":"Genes Dis"},{"key":"8105_CR3","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1159\/000339016","volume":"1","author":"DY Kim","year":"2012","unstructured":"Kim DY, Han KH. Epidemiology and surveillance of hepatocellular carcinoma. Liver Cancer. 2012;1:2\u201314.","journal-title":"Liver Cancer"},{"key":"8105_CR4","doi-asserted-by":"publisher","first-page":"207","DOI":"10.5582\/bst.2022.01199","volume":"16","author":"Y Sugawara","year":"2022","unstructured":"Sugawara Y, Hibi T. Liver transplantation for patients with hepatocellular carcinoma: its current status and advances. Biosci Trends. 2022;16:207\u201311.","journal-title":"Biosci Trends"},{"key":"8105_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.792781","volume":"12","author":"K Wang","year":"2021","unstructured":"Wang K, Wang C, Jiang H, Zhang Y, Lin W, Mo J, et al. Combination of ablation and immunotherapy for hepatocellular carcinoma: where we are and where to go. Front Immunol. 2021;12:792781.","journal-title":"Front Immunol"},{"key":"8105_CR6","doi-asserted-by":"publisher","first-page":"8165","DOI":"10.3390\/ijms21218165","volume":"21","author":"Y Chang","year":"2020","unstructured":"Chang Y, Jeong SW, Jang JY, Kim YJ. Recent updates of transarterial chemoembolization in hepatocellular carcinoma. Int J Mol Sci. 2020;21:8165.","journal-title":"Int J Mol Sci"},{"key":"8105_CR7","doi-asserted-by":"publisher","first-page":"3202","DOI":"10.3390\/biomedicines10123202","volume":"10","author":"D T\u00fcmen","year":"2022","unstructured":"T\u00fcmen D, Heumann P, G\u00fclow K, Demirci CN, Cosma LS, M\u00fcller M, et al. Pathogenesis and current treatment strategies of hepatocellular carcinoma. Biomedicines. 2022;10:3202.","journal-title":"Biomedicines"},{"key":"8105_CR8","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.3390\/cancers15061680","volume":"15","author":"DM Girardi","year":"2023","unstructured":"Girardi DM, Sousa LP, Miranda TA, Haum FNC, Pereira GCB, Pereira AAL. Systemic therapy for advanced hepatocellular carcinoma: current stand and perspectives. Cancers. 2023;15:1680.","journal-title":"Cancers"},{"key":"8105_CR9","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1038\/s43018-022-00357-2","volume":"3","author":"JM Llovet","year":"2022","unstructured":"Llovet JM, Pinyol R, Kelley RK, El-Khoueiry A, Reeves HL, Wang XW, et al. Molecular pathogenesis and systemic therapies for hepatocellular carcinoma. Nat Cancer. 2022;3:386\u2013401.","journal-title":"Nat Cancer"},{"key":"8105_CR10","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1038\/s41420-022-01094-2","volume":"8","author":"L Li","year":"2022","unstructured":"Li L, Yu S, Chen J, Quan M, Gao Y, Li Y. miR-15a and miR-20b sensitize hepatocellular carcinoma cells to sorafenib through repressing CDC37L1 and consequent PPIA downregulation. Cell Death Discov. 2022;8:297.","journal-title":"Cell Death Discov"},{"key":"8105_CR11","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.omtn.2021.12.001","volume":"27","author":"P Zhang","year":"2022","unstructured":"Zhang P, Sun H, Wen P, Wang Y, Cui Y, Wu J. circRNA circMED27 acts as a prognostic factor and mediator to promote lenvatinib resistance of hepatocellular carcinoma. Mol Ther Nucleic Acids. 2022;27:293\u2013303.","journal-title":"Mol Ther Nucleic Acids"},{"key":"8105_CR12","doi-asserted-by":"crossref","unstructured":"Oura K, Morishita A, Hamaya S, Fujita K, Masaki T. The roles of epigenetic regulation and the tumor microenvironment in the mechanism of resistance to systemic therapy in hepatocellular carcinoma. Int J Mol Sci. 2023;24:2805.","DOI":"10.3390\/ijms24032805"},{"key":"8105_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.116902","volume":"176","author":"X Su","year":"2024","unstructured":"Su X, Li Y, Ren Y, Cao M, Yang G, Luo J, et al. A new strategy for overcoming drug resistance in liver cancer: epigenetic regulation. Biomed Pharmacother. 2024;176:116902.","journal-title":"Biomed Pharmacother"},{"key":"8105_CR14","doi-asserted-by":"publisher","first-page":"e1007362","DOI":"10.1371\/journal.pgen.1007362","volume":"14","author":"A Nebbioso","year":"2018","unstructured":"Nebbioso A, Tambaro FP, Dell\u2019Aversana C, Altucci L. Cancer epigenetics: moving forward. PLoS Genet. 2018;14:e1007362.","journal-title":"PLoS Genet"},{"key":"8105_CR15","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1053\/j.gastro.2020.09.058","volume":"160","author":"WM Grady","year":"2021","unstructured":"Grady WM, Yu M, Markowitz SD. Epigenetic alterations in the gastrointestinal tract: current and emerging use for biomarkers of cancer. Gastroenterology. 2021;160:690\u2013709.","journal-title":"Gastroenterology"},{"key":"8105_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-021-02136-y","volume":"21","author":"W Xie","year":"2021","unstructured":"Xie W, Sun H, Li X, Lin F, Wang Z, Wang X. Ovarian cancer: epigenetics, drug resistance, and progression. Cancer Cell Int. 2021;21:434.","journal-title":"Cancer Cell Int"},{"key":"8105_CR17","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1038\/s41568-020-0253-2","volume":"20","author":"I Barbieri","year":"2020","unstructured":"Barbieri I, Kouzarides T. Role of RNA modifications in cancer. Nat Rev Cancer. 2020;20:303\u201322.","journal-title":"Nat Rev Cancer"},{"key":"8105_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01782-2","volume":"22","author":"H Zhuang","year":"2023","unstructured":"Zhuang H, Yu B, Tao D, Xu X, Xu Y, Wang J, et al. The role of m6A methylation in therapy resistance in cancer. Mol Cancer. 2023;22:91.","journal-title":"Mol Cancer"},{"key":"8105_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3892\/ijmm.2021.4875","volume":"47","author":"Q Li","year":"2021","unstructured":"Li Q, Li Z, Fan Z, Yang Y, Lu C. Involvement of non-coding RNAs in the pathogenesis of myocardial ischemia\/reperfusion injury. Int J Mol Med. 2021;47:1\u20131.","journal-title":"Int J Mol Med"},{"key":"8105_CR20","doi-asserted-by":"publisher","first-page":"359","DOI":"10.3109\/07853890.2015.1043140","volume":"47","author":"J Borley","year":"2015","unstructured":"Borley J, Brown R. Epigenetic mechanisms and therapeutic targets of chemotherapy resistance in epithelial ovarian cancer. Ann Med. 2015;47:359\u201369.","journal-title":"Ann Med"},{"key":"8105_CR21","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1042\/EBC20200032","volume":"65","author":"H Yan","year":"2021","unstructured":"Yan H, Bu P. Non-coding RNA in cancer. Essays Biochem. 2021;65:625\u201339.","journal-title":"Essays Biochem"},{"key":"8105_CR22","doi-asserted-by":"crossref","unstructured":"Shah M, Sarkar D. HCC-related lncRNAs: roles and mechanisms. Int J Mol Sci. 2024;25:597.","DOI":"10.3390\/ijms25010597"},{"key":"8105_CR23","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2018100836","volume":"38","author":"IL Patop","year":"2019","unstructured":"Patop IL, W\u00fcst S, Kadener S. Past, present, and future of circRNAs. EMBO J. 2019;38:e100836.","journal-title":"EMBO J"},{"key":"8105_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02224-3","volume":"24","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Yao R, Li M, Fang C, Feng K, Chen X, et al. CircTTC13 promotes sorafenib resistance in hepatocellular carcinoma through the inhibition of ferroptosis by targeting the miR-513a-5p\/SLC7A11 axis. Mol Cancer. 2025;24:32.","journal-title":"Mol Cancer"},{"key":"8105_CR25","doi-asserted-by":"publisher","first-page":"e20240043","DOI":"10.1002\/INMD.20240043","volume":"3","author":"Y Wang","year":"2025","unstructured":"Wang Y, Ma X, Zhang T, Wang L, Liu Y, Zhou G, et al. Research progress of DNA methylation in the screening of cervical cancer and precancerous lesions. Interdiscip Med. 2025;3:e20240043.","journal-title":"Interdiscip Med"},{"key":"8105_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-017-0596-9","volume":"16","author":"TB Toh","year":"2017","unstructured":"Toh TB, Lim JJ, Chow EK. Epigenetics in cancer stem cells. Mol Cancer. 2017;16:29.","journal-title":"Mol Cancer"},{"key":"8105_CR27","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7150\/ijbs.11218","volume":"11","author":"H Meng","year":"2015","unstructured":"Meng H, Cao Y, Qin J, Song X, Zhang Q, Shi Y, et al. DNA methylation, its mediators and genome integrity. Int J Biol Sci. 2015;11:604\u201317.","journal-title":"Int J Biol Sci"},{"key":"8105_CR28","doi-asserted-by":"publisher","first-page":"5589","DOI":"10.1158\/0008-5472.CAN-21-1606","volume":"81","author":"N Wajapeyee","year":"2021","unstructured":"Wajapeyee N, Gupta R. Epigenetic alterations and mechanisms that drive resistance to targeted cancer therapies. Cancer Res. 2021;81:5589\u201395.","journal-title":"Cancer Res"},{"key":"8105_CR29","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.3389\/fonc.2020.01152","volume":"10","author":"S Romero-Garcia","year":"2020","unstructured":"Romero-Garcia S, Prado-Garcia H, Carlos-Reyes A. Role of DNA methylation in the resistance to therapy in solid tumors. Front Oncol. 2020;10:1152.","journal-title":"Front Oncol"},{"key":"8105_CR30","doi-asserted-by":"publisher","first-page":"a019521","DOI":"10.1101\/cshperspect.a019521","volume":"8","author":"JE Audia","year":"2016","unstructured":"Audia JE, Campbell RM. Histone modifications and cancer. Cold Spring Harb Perspect Biol. 2016;8:a019521.","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"8105_CR31","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1007\/s13238-021-00846-7","volume":"13","author":"L Sun","year":"2022","unstructured":"Sun L, Zhang H, Gao P. Metabolic reprogramming and epigenetic modifications on the path to cancer. Protein Cell. 2022;13:877\u2013919.","journal-title":"Protein Cell"},{"key":"8105_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-020-01679-w","volume":"20","author":"S Xie","year":"2020","unstructured":"Xie S, Chen W, Chen K, Chang Y, Yang F, Lin A, et al. Emerging roles of RNA methylation in gastrointestinal cancers. Cancer Cell Int. 2020;20:585.","journal-title":"Cancer Cell Int"},{"key":"8105_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2021.105937","volume":"174","author":"B Yang","year":"2021","unstructured":"Yang B, Wang JQ, Tan Y, Yuan R, Chen ZS, Zou C. RNA methylation and cancer treatment. Pharm Res. 2021;174:105937.","journal-title":"Pharm Res"},{"key":"8105_CR34","doi-asserted-by":"publisher","first-page":"3108","DOI":"10.1080\/21655979.2022.2025701","volume":"13","author":"H Kong","year":"2022","unstructured":"Kong H, Sun J, Zhang W, Zhang H, Li H. Long intergenic non-protein coding RNA 1273 confers sorafenib resistance in hepatocellular carcinoma via regulation of methyltransferase 3. Bioengineered. 2022;13:3108\u201321.","journal-title":"Bioengineered"},{"key":"8105_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-020-01267-6","volume":"19","author":"J Li","year":"2020","unstructured":"Li J, Xie H, Ying Y, Chen H, Yan H, He L, et al. YTHDF2 mediates the mRNA degradation of the tumor suppressors to induce AKT phosphorylation in N6-methyladenosine-dependent way in prostate cancer. Mol Cancer. 2020;19:152.","journal-title":"Mol Cancer"},{"key":"8105_CR36","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1136\/gutjnl-2019-318934","volume":"69","author":"M Kudo","year":"2020","unstructured":"Kudo M, Ueshima K, Ikeda M, Torimura T, Tanabe N, Aikata H, et al. Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial. Gut. 2020;69:1492\u2013501.","journal-title":"Gut"},{"key":"8105_CR37","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"JM Llovet","year":"2008","unstructured":"Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378\u201390.","journal-title":"N Engl J Med"},{"key":"8105_CR38","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","volume":"10","author":"AL Cheng","year":"2009","unstructured":"Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10:25\u201334.","journal-title":"Lancet Oncol"},{"key":"8105_CR39","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1038\/s41575-019-0179-x","volume":"16","author":"J Bruix","year":"2019","unstructured":"Bruix J, da Fonseca LG, Reig M. Insights into the success and failure of systemic therapy for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2019;16:617\u201330.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"8105_CR40","first-page":"1229","volume":"70","author":"M Godlewski","year":"2016","unstructured":"Godlewski M, Kobyli\u0144ska A. Programmed cell death-strategy for maintenance cellular organisms homeostasis. Postepy Hig Med Dosw. 2016;70:1229\u201344.","journal-title":"Postepy Hig Med Dosw"},{"key":"8105_CR41","doi-asserted-by":"publisher","DOI":"10.1002\/smtd.202201406","volume":"7","author":"Q Meng","year":"2023","unstructured":"Meng Q, Ding B, Ma P, Lin J. Interrelation between programmed cell death and immunogenic cell death: take antitumor nanodrug as an example. Small Methods. 2023;7:e2201406.","journal-title":"Small Methods"},{"key":"8105_CR42","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1136\/bmj.322.7301.1536","volume":"322","author":"AG Renehan","year":"2001","unstructured":"Renehan AG, Booth C, Potten CS. What is apoptosis, and why is it important?. BMJ. 2001;322:1536\u20138.","journal-title":"BMJ"},{"key":"8105_CR43","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1038\/s41571-020-0341-y","volume":"17","author":"BA Carneiro","year":"2020","unstructured":"Carneiro BA, El-Deiry WS. Targeting apoptosis in cancer therapy. Nat Rev Clin Oncol. 2020;17:395\u2013417.","journal-title":"Nat Rev Clin Oncol"},{"key":"8105_CR44","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1038\/s41423-020-00630-3","volume":"18","author":"D Bertheloot","year":"2021","unstructured":"Bertheloot D, Latz E, Franklin BS. Necroptosis, pyroptosis and apoptosis: an intricate game of cell death. Cell Mol Immunol. 2021;18:1106\u201321.","journal-title":"Cell Mol Immunol"},{"key":"8105_CR45","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/1756-9966-30-87","volume":"30","author":"RS Wong","year":"2011","unstructured":"Wong RS. Apoptosis in cancer: from pathogenesis to treatment. J Exp Clin Cancer Res. 2011;30:87.","journal-title":"J Exp Clin Cancer Res"},{"key":"8105_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2022.102374","volume":"298","author":"S Lv","year":"2022","unstructured":"Lv S, Zhao X, Zhang E, Yan Y, Ma X, Li N, et al. Lysine demethylase KDM1A promotes cell growth via FKBP8-BCL2 axis in hepatocellular carcinoma. J Biol Chem. 2022;298:102374.","journal-title":"J Biol Chem"},{"key":"8105_CR47","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1007\/s13402-021-00605-0","volume":"44","author":"T Yu","year":"2021","unstructured":"Yu T, Yu J, Lu L, Zhang Y, Zhou Y, Zhou Y, et al. MT1JP-mediated miR-24-3p\/BCL2L2 axis promotes Lenvatinib resistance in hepatocellular carcinoma cells by inhibiting apoptosis. Cell Oncol. 2021;44:821\u201334.","journal-title":"Cell Oncol"},{"key":"8105_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-017-0076-6","volume":"9","author":"D Pollutri","year":"2018","unstructured":"Pollutri D, Patrizi C, Marinelli S, Giovannini C, Trombetta E, Giannone FA, et al. The epigenetically regulated miR-494 associates with stem-cell phenotype and induces sorafenib resistance in hepatocellular carcinoma. Cell Death Dis. 2018;9:4.","journal-title":"Cell Death Dis"},{"key":"8105_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-021-03827-0","volume":"12","author":"P Fern\u00e1ndez-Tussy","year":"2021","unstructured":"Fern\u00e1ndez-Tussy P, Rodr\u00edguez-Agudo R, Fern\u00e1ndez-Ramos D, Barbier-Torres L, Zubiete-Franco I, Davalillo SL, et al. Anti-miR-518d-5p overcomes liver tumor cell death resistance through mitochondrial activity. Cell Death Dis. 2021;12:555.","journal-title":"Cell Death Dis"},{"key":"8105_CR50","doi-asserted-by":"publisher","first-page":"14999","DOI":"10.1002\/jcp.27567","volume":"234","author":"S Chen","year":"2019","unstructured":"Chen S, Xia X. Long noncoding RNA NEAT1 suppresses sorafenib sensitivity of hepatocellular carcinoma cells via regulating miR-335-c-Met. J Cell Physiol. 2019;234:14999\u20135009.","journal-title":"J Cell Physiol"},{"key":"8105_CR51","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-021-04491-0","volume":"13","author":"ZB Dong","year":"2022","unstructured":"Dong ZB, Wu HM, He YC, Huang ZT, Weng YH, Li H, et al. MiRNA-124-3p.1 sensitizes hepatocellular carcinoma cells to sorafenib by regulating FOXO3a by targeting AKT2 and SIRT1. Cell Death Dis. 2022;13:35.","journal-title":"Cell Death Dis"},{"key":"8105_CR52","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.1038\/s41416-022-01759-w","volume":"126","author":"YY Shao","year":"2022","unstructured":"Shao YY, Chen PS, Lin LI, Lee BS, Ling A, Cheng AL, et al. Low miR-10b-3p associated with sorafenib resistance in hepatocellular carcinoma. Br J Cancer. 2022;126:1806\u201314.","journal-title":"Br J Cancer"},{"key":"8105_CR53","doi-asserted-by":"publisher","first-page":"4608","DOI":"10.7150\/ijbs.86227","volume":"19","author":"Y Ruan","year":"2023","unstructured":"Ruan Y, Chen T, Zheng L, Cai J, Zhao H, Wang Y, et al. cDCBLD2 mediates sorafenib resistance in hepatocellular carcinoma by sponging miR-345-5p binding to the TOP2A coding sequence. Int J Biol Sci. 2023;19:4608\u201326.","journal-title":"Int J Biol Sci"},{"key":"8105_CR54","doi-asserted-by":"publisher","DOI":"10.1002\/EXP.20240002","volume":"5","author":"X Bai","year":"2025","unstructured":"Bai X, Kang J, Wei S, Wang Y, Liu Y, Yuan B, et al. A pH responsive nanocomposite for combination sonodynamic-immunotherapy with ferroptosis and calcium ion overload via SLC7A11\/ACSL4\/LPCAT3 pathway. Exploration. 2025;5:20240002.","journal-title":"Exploration"},{"key":"8105_CR55","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/s41422-020-00441-1","volume":"31","author":"D Tang","year":"2021","unstructured":"Tang D, Chen X, Kang R, Kroemer G. Ferroptosis: molecular mechanisms and health implications. Cell Res. 2021;31:107\u201325.","journal-title":"Cell Res"},{"key":"8105_CR56","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1038\/s41580-020-00324-8","volume":"22","author":"X Jiang","year":"2021","unstructured":"Jiang X, Stockwell BR, Conrad M. Ferroptosis: mechanisms, biology and role in disease. Nat Rev Mol Cell Biol. 2021;22:266\u201382.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"8105_CR57","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.1097\/CM9.0000000000002327","volume":"135","author":"T Cong","year":"2022","unstructured":"Cong T, Luo Y, Fu Y, Liu Y, Li Y, Li X. New perspectives on ferroptosis and its role in hepatocellular carcinoma. Chin Med J. 2022;135:2157\u201366.","journal-title":"Chin Med J"},{"key":"8105_CR58","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-2298-2","volume":"11","author":"J Li","year":"2020","unstructured":"Li J, Cao F, Yin HL, Huang ZJ, Lin ZT, Mao N, et al. Ferroptosis: past, present and future. Cell Death Dis. 2020;11:88.","journal-title":"Cell Death Dis"},{"key":"8105_CR59","doi-asserted-by":"publisher","first-page":"22240","DOI":"10.1021\/acsnano.3c01199","volume":"17","author":"Y Gao","year":"2023","unstructured":"Gao Y, Tong M, Wong TL, Ng KY, Xie YN, Wang Z, et al. Long noncoding RNA URB1-antisense RNA 1 (AS1) suppresses sorafenib-induced ferroptosis in hepatocellular carcinoma by driving ferritin phase separation. ACS Nano. 2023;17:22240\u201358.","journal-title":"ACS Nano"},{"key":"8105_CR60","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s12672-023-00761-9","volume":"14","author":"F Chen","year":"2023","unstructured":"Chen F, Wang L. Long noncoding RNA CASC11 suppresses sorafenib-triggered ferroptosis via stabilizing SLC7A11 mRNA in hepatocellular carcinoma cells. Discov Oncol. 2023;14:145.","journal-title":"Discov Oncol"},{"key":"8105_CR61","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.1300","volume":"13","author":"Z Shi","year":"2023","unstructured":"Shi Z, Li Z, Jin B, Ye W, Wang L, Zhang S, et al. Loss of LncRNA DUXAP8 synergistically enhanced sorafenib induced ferroptosis in hepatocellular carcinoma via SLC7A11 de-palmitoylation. Clin Transl Med. 2023;13:e1300.","journal-title":"Clin Transl Med"},{"key":"8105_CR62","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2024.101181","volume":"78","author":"CJ Shi","year":"2025","unstructured":"Shi CJ, Pang FX, Lei YH, Deng LQ, Pan FZ, Liang ZQ, et al. 5-methylcytosine methylation of MALAT1 promotes resistance to sorafenib in hepatocellular carcinoma through ELAVL1\/SLC7A11-mediated ferroptosis. Drug Resist Updat. 2025;78:101181.","journal-title":"Drug Resist Updat"},{"key":"8105_CR63","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1186\/s13046-024-03061-4","volume":"43","author":"J Li","year":"2024","unstructured":"Li J, Li Y, Wang D, Liao R, Wu Z. PLAG1 interacts with GPX4 to conquer vulnerability to sorafenib induced ferroptosis through a PVT1\/miR-195-5p axis-dependent manner in hepatocellular carcinoma. J Exp Clin Cancer Res. 2024;43:143.","journal-title":"J Exp Clin Cancer Res"},{"key":"8105_CR64","doi-asserted-by":"publisher","first-page":"2843","DOI":"10.1038\/s41418-021-00859-z","volume":"28","author":"X Chen","year":"2021","unstructured":"Chen X, Kang R, Kroemer G, Tang D. Organelle-specific regulation of ferroptosis. Cell Death Differ. 2021;28:2843\u201356.","journal-title":"Cell Death Differ"},{"key":"8105_CR65","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/nchembio.2239","volume":"13","author":"S Doll","year":"2017","unstructured":"Doll S, Proneth B, Tyurina YY, Panzilius E, Kobayashi S, Ingold I, et al. ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition. Nat Chem Biol. 2017;13:91\u20138.","journal-title":"Nat Chem Biol"},{"key":"8105_CR66","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1097\/CM9.0000000000002533","volume":"136","author":"K Ding","year":"2023","unstructured":"Ding K, Liu C, Li L, Yang M, Jiang N, Luo S, et al. Acyl-CoA synthase ACSL4: an essential target in ferroptosis and fatty acid metabolism. Chin Med J. 2023;136:2521\u201337.","journal-title":"Chin Med J"},{"key":"8105_CR67","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s13046-021-02208-x","volume":"41","author":"Y Lu","year":"2022","unstructured":"Lu Y, Chan YT, Tan HY, Zhang C, Guo W, Xu Y, et al. Epigenetic regulation of ferroptosis via ETS1\/miR-23a-3p\/ACSL4 axis mediates sorafenib resistance in human hepatocellular carcinoma. J Exp Clin Cancer Res. 2022;41:3.","journal-title":"J Exp Clin Cancer Res"},{"key":"8105_CR68","doi-asserted-by":"publisher","first-page":"7088","DOI":"10.7150\/thno.99197","volume":"14","author":"Y Zhao","year":"2024","unstructured":"Zhao Y, Han S, Zeng Z, Zheng H, Li Y, Wang F, et al. Decreased lncRNA HNF4A-AS1 facilitates resistance to sorafenib-induced ferroptosis of hepatocellular carcinoma by reprogramming lipid metabolism. Theranostics. 2024;14:7088\u2013110.","journal-title":"Theranostics"},{"key":"8105_CR69","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/S0092-8674(04)00130-8","volume":"116","author":"Y Cheng","year":"2004","unstructured":"Cheng Y, Zak O, Aisen P, Harrison SC, Walz T. Structure of the human transferrin receptor-transferrin complex. Cell. 2004;116:565\u201376.","journal-title":"Cell"},{"key":"8105_CR70","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-023-01267-1","volume":"21","author":"Y Li","year":"2023","unstructured":"Li Y, Du Y, Zhou Y, Chen Q, Luo Z, Ren Y, et al. Iron and copper: critical executioners of ferroptosis, cuproptosis and other forms of cell death. Cell Commun Signal. 2023;21:327.","journal-title":"Cell Commun Signal"},{"key":"8105_CR71","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S0168-8278(01)00222-7","volume":"36","author":"G Zanninelli","year":"2002","unstructured":"Zanninelli G, Lor\u00e9al O, Brissot P, Konijn AM, Slotki IN, Hider RC, et al. The labile iron pool of hepatocytes in chronic and acute iron overload and chelator-induced iron deprivation. J Hepatol. 2002;36:39\u201346.","journal-title":"J Hepatol"},{"key":"8105_CR72","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.freeradbiomed.2021.01.026","volume":"170","author":"V Camarena","year":"2021","unstructured":"Camarena V, Huff TC, Wang G. Epigenomic regulation by labile iron. Free Radic Biol Med. 2021;170:44\u20139.","journal-title":"Free Radic Biol Med"},{"key":"8105_CR73","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/s41420-023-01660-2","volume":"9","author":"J Sun","year":"2023","unstructured":"Sun J, Liu Q, Jiang Y, Cai Z, Liu H, Zuo H. Engineered small extracellular vesicles loaded with miR-654-5p promote ferroptosis by targeting HSPB1 to alleviate sorafenib resistance in hepatocellular carcinoma. Cell Death Discov. 2023;9:362.","journal-title":"Cell Death Discov"},{"key":"8105_CR74","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1111\/cas.16186","volume":"115","author":"Y Lai","year":"2024","unstructured":"Lai Y, Han X, Xie B, Xu Y, Yang Z, Wang D, et al. EZH2 suppresses ferroptosis in hepatocellular carcinoma and reduces sorafenib sensitivity through epigenetic regulation of TFR2. Cancer Sci. 2024;115:2220\u201334.","journal-title":"Cancer Sci"},{"key":"8105_CR75","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2024.101052","volume":"73","author":"SH Hao","year":"2024","unstructured":"Hao SH, Ma XD, Xu L, Xie JD, Feng ZH, Chen JW, et al. Dual specific phosphatase 4 suppresses ferroptosis and enhances sorafenib resistance in hepatocellular carcinoma. Drug Resist Updat. 2024;73:101052.","journal-title":"Drug Resist Updat"},{"key":"8105_CR76","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1038\/s41580-023-00585-z","volume":"24","author":"J Debnath","year":"2023","unstructured":"Debnath J, Gammoh N, Ryan KM. Autophagy and autophagy-related pathways in cancer. Nat Rev Mol Cell Biol. 2023;24:560\u201375.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"8105_CR77","doi-asserted-by":"publisher","DOI":"10.1002\/VIW.20240003","volume":"5","author":"C Qian","year":"2024","unstructured":"Qian C, Zhang Y, Chen X, Zhu C, Dong X, Chen W, et al. Nanomedicine-encouraged cellular autophagy promoters favor liver fibrosis progression reversal. View. 2024;5:20240003.","journal-title":"View"},{"key":"8105_CR78","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2021108863","volume":"40","author":"DJ Klionsky","year":"2021","unstructured":"Klionsky DJ, Petroni G, Amaravadi RK, Baehrecke EH, Ballabio A, Boya P, et al. Autophagy in major human diseases. EMBO J. 2021;40:e108863.","journal-title":"EMBO J"},{"key":"8105_CR79","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1186\/s13046-019-1177-0","volume":"38","author":"W Li","year":"2019","unstructured":"Li W, Dong X, He C, Tan G, Li Z, Zhai B, et al. LncRNA SNHG1 contributes to sorafenib resistance by activating the Akt pathway and is positively regulated by miR-21 in hepatocellular carcinoma cells. J Exp Clin Cancer Res. 2019;38:183.","journal-title":"J Exp Clin Cancer Res"},{"key":"8105_CR80","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1158\/1535-7163.MCT-13-1043","volume":"13","author":"B Zhai","year":"2014","unstructured":"Zhai B, Hu F, Jiang X, Xu J, Zhao D, Liu B, et al. Inhibition of Akt reverses the acquired resistance to sorafenib by switching protective autophagy to autophagic cell death in hepatocellular carcinoma. Mol Cancer Ther. 2014;13:1589\u201398.","journal-title":"Mol Cancer Ther"},{"key":"8105_CR81","doi-asserted-by":"publisher","first-page":"257","DOI":"10.7150\/ijms.67352","volume":"19","author":"X Feng","year":"2022","unstructured":"Feng X, Zou B, Nan T, Zheng X, Zheng L, Lan J, et al. MiR-25 enhances autophagy and promotes sorafenib resistance of hepatocellular carcinoma via targeting FBXW7. Int J Med Sci. 2022;19:257\u201366.","journal-title":"Int J Med Sci"},{"key":"8105_CR82","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2023.121773","volume":"325","author":"Z Hu","year":"2023","unstructured":"Hu Z, Zhao Y, Mang Y, Zhu J, Yu L, Li L, et al. MiR-21-5p promotes sorafenib resistance and hepatocellular carcinoma progression by regulating SIRT7 ubiquitination through USP24. Life Sci. 2023;325:121773.","journal-title":"Life Sci"},{"key":"8105_CR83","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s13046-019-1516-1","volume":"39","author":"M Ding","year":"2020","unstructured":"Ding M, Jiang CY, Zhang Y, Zhao J, Han BM, Xia SJ. SIRT7 depletion inhibits cell proliferation and androgen-induced autophagy by suppressing the AR signaling in prostate cancer. J Exp Clin Cancer Res. 2020;39:28.","journal-title":"J Exp Clin Cancer Res"},{"key":"8105_CR84","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.3390\/cancers13133227","volume":"13","author":"MY Chen","year":"2021","unstructured":"Chen MY, Yadav VK, Chu YC, Ong JR, Huang TY, Lee KF, et al. Hydroxychloroquine (HCQ) modulates autophagy and oxidative DNA damage stress in hepatocellular carcinoma to overcome sorafenib resistance via TLR9\/SOD1\/hsa-miR-30a-5p\/Beclin-1 axis. Cancers. 2021;13:3227.","journal-title":"Cancers"},{"key":"8105_CR85","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.canlet.2017.08.039","volume":"409","author":"N Zhang","year":"2017","unstructured":"Zhang N, Wu Y, Lyu X, Li B, Yan X, Xiong H, et al. HSF1 upregulates ATG4B expression and enhances epirubicin-induced protective autophagy in hepatocellular carcinoma cells. Cancer Lett. 2017;409:81\u201390.","journal-title":"Cancer Lett"},{"key":"8105_CR86","doi-asserted-by":"publisher","first-page":"687524","DOI":"10.3389\/fcell.2021.687524","volume":"9","author":"L Chen","year":"2021","unstructured":"Chen L, Sun L, Dai X, Li T, Yan X, Zhang Y, et al. LncRNA CRNDE promotes ATG4B-mediated autophagy and alleviates the sensitivity of sorafenib in hepatocellular carcinoma cells. Front Cell Dev Biol. 2021;9:687524.","journal-title":"Front Cell Dev Biol"},{"key":"8105_CR87","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2019103181","volume":"39","author":"Z Lin","year":"2020","unstructured":"Lin Z, Niu Y, Wan A, Chen D, Liang H, Chen X, et al. RNA m(6)A methylation regulates sorafenib resistance in liver cancer through FOXO3-mediated autophagy. EMBO J. 2020;39:e103181.","journal-title":"EMBO J"},{"key":"8105_CR88","doi-asserted-by":"publisher","first-page":"3006","DOI":"10.1172\/JCI127201","volume":"129","author":"Y Cao","year":"2019","unstructured":"Cao Y. Adipocyte and lipid metabolism in cancer drug resistance. J Clin Invest. 2019;129:3006\u201317.","journal-title":"J Clin Invest"},{"key":"8105_CR89","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1038\/s41392-023-01442-3","volume":"8","author":"M You","year":"2023","unstructured":"You M, Xie Z, Zhang N, Zhang Y, Xiao D, Liu S, et al. Signaling pathways in cancer metabolism: mechanisms and therapeutic targets. Signal Transduct Target Ther. 2023;8:196.","journal-title":"Signal Transduct Target Ther"},{"key":"8105_CR90","first-page":"765","volume":"9","author":"M Zhang","year":"2019","unstructured":"Zhang M, Zhang H, Hong H, Zhang Z. MiR-374b re-sensitizes hepatocellular carcinoma cells to sorafenib therapy by antagonizing PKM2-mediated glycolysis pathway. Am J Cancer Res. 2019;9:765\u201378.","journal-title":"Am J Cancer Res"},{"key":"8105_CR91","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1016\/j.omtn.2021.09.014","volume":"26","author":"B Zhou","year":"2021","unstructured":"Zhou B, Lu D, Wang A, Cui J, Zhang L, Li J, et al. Endoplasmic reticulum stress promotes sorafenib resistance via miR-188-5p\/hnRNPA2B1-mediated upregulation of PKM2 in hepatocellular carcinoma. Mol Ther Nucleic Acids. 2021;26:1051\u201365.","journal-title":"Mol Ther Nucleic Acids"},{"key":"8105_CR92","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-03123-3","volume":"11","author":"Z Zhang","year":"2020","unstructured":"Zhang Z, Tan X, Luo J, Yao H, Si Z, Tong JS. The miR-30a-5p\/CLCF1 axis regulates sorafenib resistance and aerobic glycolysis in hepatocellular carcinoma. Cell Death Dis. 2020;11:902.","journal-title":"Cell Death Dis"},{"key":"8105_CR93","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s13046-023-02718-w","volume":"42","author":"C Bergamini","year":"2023","unstructured":"Bergamini C, Leoni I, Rizzardi N, Melli M, Galvani G, Coada CA, et al. MiR-494 induces metabolic changes through G6pc targeting and modulates sorafenib response in hepatocellular carcinoma. J Exp Clin Cancer Res. 2023;42:145.","journal-title":"J Exp Clin Cancer Res"},{"key":"8105_CR94","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s40880-018-0301-4","volume":"38","author":"C Cheng","year":"2018","unstructured":"Cheng C, Geng F, Cheng X, Guo D. Lipid metabolism reprogramming and its potential targets in cancer. Cancer Commun. 2018;38:27.","journal-title":"Cancer Commun"},{"key":"8105_CR95","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","volume":"24","author":"SL Friedman","year":"2018","unstructured":"Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies. Nat Med. 2018;24:908\u201322.","journal-title":"Nat Med"},{"key":"8105_CR96","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1038\/s41420-022-01234-8","volume":"8","author":"H Wang","year":"2022","unstructured":"Wang H, Wang Y, Lai S, Zhao L, Liu W, Liu S, et al. LINC01468 drives NAFLD-HCC progression through CUL4A-linked degradation of SHIP2. Cell Death Discov. 2022;8:449.","journal-title":"Cell Death Discov"},{"key":"8105_CR97","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-01988-y","volume":"23","author":"YT Chan","year":"2024","unstructured":"Chan YT, Wu J, Lu Y, Li Q, Feng Z, Xu L, et al. Loss of lncRNA LINC01056 leads to sorafenib resistance in HCC. Mol Cancer. 2024;23:74.","journal-title":"Mol Cancer"},{"key":"8105_CR98","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1038\/s41556-018-0125-0","volume":"20","author":"LB Sullivan","year":"2018","unstructured":"Sullivan LB, Luengo A, Danai LV, Bush LN, Diehl FF, Hosios AM, et al. Aspartate is an endogenous metabolic limitation for tumour growth. Nat Cell Biol. 2018;20:782\u20138.","journal-title":"Nat Cell Biol"},{"key":"8105_CR99","doi-asserted-by":"publisher","first-page":"2354","DOI":"10.1016\/j.ymthe.2022.02.020","volume":"30","author":"M Chen","year":"2022","unstructured":"Chen M, Zhang C, Liu W, Du X, Liu X, Xing B. Long noncoding RNA LINC01234 promotes hepatocellular carcinoma progression through orchestrating aspartate metabolic reprogramming. Mol Ther. 2022;30:2354\u201369.","journal-title":"Mol Ther"},{"key":"8105_CR100","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2023.103920","volume":"182","author":"N Ebrahimi","year":"2023","unstructured":"Ebrahimi N, Afshinpour M, Fakhr SS, Kalkhoran PG, Shadman-Manesh V, Adelian S, et al. Cancer stem cells in colorectal cancer: signaling pathways involved in stemness and therapy resistance. Crit Rev Oncol Hematol. 2023;182:103920.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"6","key":"8105_CR101","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.3390\/cells10061528","volume":"10","author":"I Skvortsova","year":"2021","unstructured":"Skvortsova I. Cancer stem cells: what do we know about them?. Cells. 2021;10(6):1523.","journal-title":"Cells"},{"key":"8105_CR102","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-017-0669-9","volume":"16","author":"A Liu","year":"2017","unstructured":"Liu A, Zhu J, Wu G, Cao L, Tan Z, Zhang S, et al. Antagonizing miR-455-3p inhibits chemoresistance and aggressiveness in esophageal squamous cell carcinoma. Mol Cancer. 2017;16:106.","journal-title":"Mol Cancer"},{"key":"8105_CR103","doi-asserted-by":"publisher","first-page":"8381","DOI":"10.1002\/jcp.27740","volume":"234","author":"M Najafi","year":"2019","unstructured":"Najafi M, Farhood B, Mortezaee K. Cancer stem cells (CSCs) in cancer progression and therapy. J Cell Physiol. 2019;234:8381\u201395.","journal-title":"J Cell Physiol"},{"key":"8105_CR104","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1007\/s13577-023-00945-z","volume":"36","author":"H He","year":"2023","unstructured":"He H, Zhou J, Cheng F, Li H, Quan Y. MiR-3677-3p promotes development and sorafenib resistance of hepatitis B-related hepatocellular carcinoma by inhibiting FOXM1 ubiquitination. Hum Cell. 2023;36:1773\u201389.","journal-title":"Hum Cell"},{"key":"8105_CR105","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.semcancer.2022.07.009","volume":"86","author":"G Sher","year":"2022","unstructured":"Sher G, Masoodi T, Patil K, Akhtar S, Kuttikrishnan S, Ahmad A, et al. Dysregulated FOXM1 signaling in the regulation of cancer stem cells. Semin Cancer Biol. 2022;86:107\u201321.","journal-title":"Semin Cancer Biol"},{"key":"8105_CR106","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-024-03288-3","volume":"24","author":"T Cheng","year":"2024","unstructured":"Cheng T, Zhou C, Bian S, Sobeck K, Liu Y. Coordinated activation of DNMT3a and TET2 in cancer stem cell-like cells initiates and sustains drug resistance in hepatocellular carcinoma. Cancer Cell Int. 2024;24:110.","journal-title":"Cancer Cell Int"},{"key":"8105_CR107","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1158\/0008-5472.CAN-20-3044","volume":"81","author":"L Bi","year":"2021","unstructured":"Bi L, Ren Y, Feng M, Meng P, Wang Q, Chen W, et al. HDAC11 regulates glycolysis through the LKB1\/AMPK signaling pathway to maintain hepatocellular carcinoma stemness. Cancer Res. 2021;81:2015\u201328.","journal-title":"Cancer Res"},{"key":"8105_CR108","doi-asserted-by":"publisher","DOI":"10.1016\/j.abb.2021.108871","volume":"703","author":"J Li","year":"2021","unstructured":"Li J, Zhong X, Wang X, Xu F, Yang J, Lu J, et al. miR-93 regulates liver tumor initiating cells expansion and predicts chemotherapeutic response of patients. Arch Biochem Biophys. 2021;703:108871.","journal-title":"Arch Biochem Biophys"},{"key":"8105_CR109","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.7150\/jca.52395","volume":"12","author":"S Qu","year":"2021","unstructured":"Qu S, Zhang X, Wu Y, Li H, Zhai J, Wu D. miR-361-3p regulates liver tumor-initiating cells expansion and chemo-resistance. J Cancer. 2021;12:1483\u201392.","journal-title":"J Cancer"},{"key":"8105_CR110","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1097\/CAD.0000000000001329","volume":"33","author":"J Liu","year":"2022","unstructured":"Liu J, Nie C. KDM5B regulates the PTEN\/PI3K\/Akt pathway to increase sorafenib-resistance in hepatocellular carcinoma. Anticancer Drugs. 2022;33:840\u20139.","journal-title":"Anticancer Drugs"},{"key":"8105_CR111","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1186\/s13046-019-1442-2","volume":"38","author":"SC Lai","year":"2019","unstructured":"Lai SC, Su YT, Chi CC, Kuo YC, Lee KF, Wu YC, et al. DNMT3b\/OCT4 expression confers sorafenib resistance and poor prognosis of hepatocellular carcinoma through IL-6\/STAT3 regulation. J Exp Clin Cancer Res. 2019;38:474.","journal-title":"J Exp Clin Cancer Res"},{"key":"8105_CR112","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1038\/s41420-024-01985-6","volume":"10","author":"C Wang","year":"2024","unstructured":"Wang C, Dong R, Yang F, Zheng L, Liu Y, Yan Y, et al. LARP4B promotes hepatocellular carcinoma progression and impairs sorafenib efficacy by activating SPINK1-mediated EGFR pathway. Cell Death Discov. 2024;10:208.","journal-title":"Cell Death Discov"},{"key":"8105_CR113","doi-asserted-by":"publisher","first-page":"5174","DOI":"10.3748\/wjg.v30.i48.5174","volume":"30","author":"Y Yu","year":"2024","unstructured":"Yu Y, Lu XH, Mu JS, Meng JY, Sun JS, Chen HX, et al. N6-methyladenosine-modified long non-coding RNA KIF9-AS1 promotes stemness and sorafenib resistance in hepatocellular carcinoma by upregulating SHOX2 expression. World J Gastroenterol. 2024;30:5174\u201390.","journal-title":"World J Gastroenterol"},{"key":"8105_CR114","doi-asserted-by":"publisher","first-page":"5848","DOI":"10.3390\/ijms23105848","volume":"23","author":"G Manfioletti","year":"2022","unstructured":"Manfioletti G, Fedele M. Epithelial-mesenchymal transition (EMT) 2021. Int J Mol Sci. 2022;23:5848.","journal-title":"Int J Mol Sci"},{"key":"8105_CR115","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1038\/nrm3758","volume":"15","author":"S Lamouille","year":"2014","unstructured":"Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 2014;15:178\u201396.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"8105_CR116","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.ceb.2005.08.001","volume":"17","author":"MA Huber","year":"2005","unstructured":"Huber MA, Kraut N, Beug H. Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr Opin Cell Biol. 2005;17:548\u201358.","journal-title":"Curr Opin Cell Biol"},{"key":"8105_CR117","doi-asserted-by":"publisher","first-page":"261","DOI":"10.3724\/abbs.2021019","volume":"54","author":"J Sun","year":"2022","unstructured":"Sun J, Zheng X, Wang B, Cai Y, Zheng L, Hu L, et al. LncRNA LIMT (LINC01089) contributes to sorafenib chemoresistance via regulation of miR-665 and epithelial to mesenchymal transition in hepatocellular carcinoma cells. Acta Biochim Biophys Sin. 2022;54:261\u201370.","journal-title":"Acta Biochim Biophys Sin"},{"key":"8105_CR118","doi-asserted-by":"publisher","first-page":"165","DOI":"10.3892\/or.2020.7608","volume":"44","author":"Y Xu","year":"2020","unstructured":"Xu Y, Liu Y, Li Z, Li H, Li X, Yan L, et al. Long non-coding RNA H19 is involved in sorafenib resistance in hepatocellular carcinoma by upregulating miR-675. Oncol Rep. 2020;44:165\u201373.","journal-title":"Oncol Rep"},{"key":"8105_CR119","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e27322","volume":"10","author":"K Xu","year":"2024","unstructured":"Xu K, Wang X, Hu S, Tang J, Liu S, Chen H, et al. LINC00540 promotes sorafenib resistance and functions as a ceRNA for miR-4677-3p to regulate AKR1C2 in hepatocellular carcinoma. Heliyon. 2024;10:e27322.","journal-title":"Heliyon"},{"key":"8105_CR120","doi-asserted-by":"publisher","first-page":"4917","DOI":"10.3390\/cancers13194917","volume":"13","author":"A Hirao","year":"2021","unstructured":"Hirao A, Sato Y, Tanaka H, Nishida K, Tomonari T, Hirata M, et al. MiR-125b-5p is involved in sorafenib resistance through ataxin-1-mediated epithelial-mesenchymal transition in hepatocellular carcinoma. Cancers. 2021;13:4917.","journal-title":"Cancers"},{"key":"8105_CR121","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.783385","volume":"9","author":"Z Liu","year":"2021","unstructured":"Liu Z, Lu J, Fang H, Sheng J, Cui M, Yang Y, et al. m6A modification-mediated DUXAP8 regulation of malignant phenotype and chemotherapy resistance of hepatocellular carcinoma through miR-584-5p\/MAPK1\/ERK pathway axis. Front Cell Dev Biol. 2021;9:783385.","journal-title":"Front Cell Dev Biol"},{"key":"8105_CR122","doi-asserted-by":"publisher","first-page":"7222","DOI":"10.1002\/cam4.5432","volume":"12","author":"Y Kuang","year":"2023","unstructured":"Kuang Y, Cheng Y, Wang J, Li H, Cao X, Wang Y. KIAA1429 mediates epithelial mesenchymal transition in sorafenib-resistant hepatocellular carcinoma through m6A methylation modification. Cancer Med. 2023;12:7222\u201333.","journal-title":"Cancer Med"},{"key":"8105_CR123","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-021-01361-3","volume":"20","author":"ZR Dong","year":"2021","unstructured":"Dong ZR, Ke AW, Li T, Cai JB, Yang YF, Zhou W, et al. CircMEMO1 modulates the promoter methylation and expression of TCF21 to regulate hepatocellular carcinoma progression and sorafenib treatment sensitivity. Mol Cancer. 2021;20:75.","journal-title":"Mol Cancer"},{"key":"8105_CR124","doi-asserted-by":"publisher","first-page":"7058","DOI":"10.18632\/oncotarget.27361","volume":"10","author":"A Zheng","year":"2019","unstructured":"Zheng A, Chevalier N, Calderoni M, Dubuis G, Dormond O, Ziros PG, et al. CRISPR\/Cas9 genome-wide screening identifies KEAP1 as a sorafenib, lenvatinib, and regorafenib sensitivity gene in hepatocellular carcinoma. Oncotarget. 2019;10:7058\u201370.","journal-title":"Oncotarget"},{"key":"8105_CR125","doi-asserted-by":"publisher","first-page":"5464","DOI":"10.7150\/thno.54822","volume":"11","author":"FH Kong","year":"2021","unstructured":"Kong FH, Ye QF, Miao XY, Liu X, Huang SQ, Xiong L, et al. Current status of sorafenib nanoparticle delivery systems in the treatment of hepatocellular carcinoma. Theranostics. 2021;11:5464\u201390.","journal-title":"Theranostics"},{"key":"8105_CR126","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/nrclinonc.2018.28","volume":"15","author":"F Janku","year":"2018","unstructured":"Janku F, Yap TA, Meric-Bernstam F. Targeting the PI3K pathway in cancer: are we making headway?. Nat Rev Clin Oncol. 2018;15:273\u201391.","journal-title":"Nat Rev Clin Oncol"},{"key":"8105_CR127","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1038\/s12276-022-00887-w","volume":"54","author":"A Christine","year":"2022","unstructured":"Christine A, Park MK, Song SJ, Song MS. The equilibrium of tumor suppression: DUBs as active regulators of PTEN. Exp Mol Med. 2022;54:1814\u201321.","journal-title":"Exp Mol Med"},{"key":"8105_CR128","doi-asserted-by":"publisher","first-page":"64","DOI":"10.3389\/fonc.2014.00064","volume":"4","author":"C Porta","year":"2014","unstructured":"Porta C, Paglino C, Mosca A. Targeting PI3K\/Akt\/mTOR signaling in cancer. Front Oncol. 2014;4:64.","journal-title":"Front Oncol"},{"key":"8105_CR129","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/j.biopha.2018.06.097","volume":"105","author":"XM Jiang","year":"2018","unstructured":"Jiang XM, Yu XN, Liu TT, Zhu HR, Shi X, Bilegsaikhan E, et al. microRNA-19a-3p promotes tumor metastasis and chemoresistance through the PTEN\/Akt pathway in hepatocellular carcinoma. Biomed Pharmacother. 2018;105:1147\u201354.","journal-title":"Biomed Pharmacother"},{"key":"8105_CR130","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcp.2022.101877","volume":"67","author":"X Li","year":"2023","unstructured":"Li X, Yin X, Bao H, Liu C. Circular RNA ITCH increases sorafenib-sensitivity in hepatocellular carcinoma via sequestering miR-20b-5p and modulating the downstream PTEN-PI3K\/Akt pathway. Mol Cell Probes. 2023;67:101877.","journal-title":"Mol Cell Probes"},{"key":"8105_CR131","doi-asserted-by":"publisher","first-page":"5436","DOI":"10.3390\/ijms21155436","volume":"21","author":"PK Wu","year":"2020","unstructured":"Wu PK, Becker A, Park JI. Growth inhibitory signaling of the Raf\/MEK\/ERK pathway. Int J Mol Sci. 2020;21:5436.","journal-title":"Int J Mol Sci"},{"key":"8105_CR132","doi-asserted-by":"publisher","first-page":"3045","DOI":"10.3892\/ol.2016.5110","volume":"12","author":"L Li","year":"2016","unstructured":"Li L, Zhao GD, Shi Z, Qi LL, Zhou LY, Fu ZX. The Ras\/Raf\/MEK\/ERK signaling pathway and its role in the occurrence and development of HCC. Oncol Lett. 2016;12:3045\u201350.","journal-title":"Oncol Lett"},{"key":"8105_CR133","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.ccr.2011.01.001","volume":"19","author":"J Hou","year":"2011","unstructured":"Hou J, Lin L, Zhou W, Wang Z, Ding G, Dong Q, et al. Identification of miRNomes in human liver and hepatocellular carcinoma reveals miR-199a\/b-3p as therapeutic target for hepatocellular carcinoma. Cancer Cell. 2011;19:232\u201343.","journal-title":"Cancer Cell"},{"key":"8105_CR134","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.1016\/j.ymthe.2021.04.011","volume":"29","author":"W Song","year":"2021","unstructured":"Song W, Zheng C, Liu M, Xu Y, Qian Y, Zhang Z, et al. TRERNA1 upregulation mediated by HBx promotes sorafenib resistance and cell proliferation in HCC via targeting NRAS by sponging miR-22-3p. Mol Ther. 2021;29:2601\u201316.","journal-title":"Mol Ther"},{"key":"8105_CR135","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/s41392-020-00375-5","volume":"5","author":"J Xu","year":"2020","unstructured":"Xu J, Ji L, Liang Y, Wan Z, Zheng W, Song X, et al. CircRNA-SORE mediates sorafenib resistance in hepatocellular carcinoma by stabilizing YBX1. Signal Transduct Target Ther. 2020;5:298.","journal-title":"Signal Transduct Target Ther"},{"key":"8105_CR136","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1158\/0008-5472.CAN-17-2432","volume":"78","author":"Y Liu","year":"2018","unstructured":"Liu Y, Zhang X, Yang B, Zhuang H, Guo H, Wei W, et al. Demethylation-induced overexpression of Shc3 drives c-Raf-independent activation of MEK\/ERK in HCC. Cancer Res. 2018;78:2219\u201332.","journal-title":"Cancer Res"},{"key":"8105_CR137","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-021-03560-8","volume":"12","author":"Y Liu","year":"2021","unstructured":"Liu Y, Zhuang H, Cao F, Li J, Guo Y, Zhang J, et al. Shc3 promotes hepatocellular carcinoma stemness and drug resistance by interacting with \u03b2-catenin to inhibit its ubiquitin degradation pathway. Cell Death Dis. 2021;12:278.","journal-title":"Cell Death Dis"},{"key":"8105_CR138","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/s41420-023-01469-z","volume":"9","author":"Y Sha","year":"2023","unstructured":"Sha Y, Pan M, Chen Y, Qiao L, Zhou H, Liu D, et al. PLEKHG5 is stabilized by HDAC2-related deacetylation and confers sorafenib resistance in hepatocellular carcinoma. Cell Death Discov. 2023;9:176.","journal-title":"Cell Death Discov"},{"key":"8105_CR139","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.canlet.2019.05.010","volume":"457","author":"SW Fung","year":"2019","unstructured":"Fung SW, Cheung PF, Yip CW, Ng LW, Cheung TT, Chong CC, et al. The ATP-binding cassette transporter ABCF1 is a hepatic oncofetal protein that promotes chemoresistance, EMT and cancer stemness in hepatocellular carcinoma. Cancer Lett. 2019;457:98\u2013109.","journal-title":"Cancer Lett"},{"key":"8105_CR140","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s12929-021-00752-4","volume":"28","author":"TT Li","year":"2021","unstructured":"Li TT, Mou J, Pan YJ, Huo FC, Du WQ, Liang J, et al. MicroRNA-138-1-3p sensitizes sorafenib to hepatocellular carcinoma by targeting PAK5 mediated \u03b2-catenin\/ABCB1 signaling pathway. J Biomed Sci. 2021;28:56.","journal-title":"J Biomed Sci"},{"key":"8105_CR141","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-41552-8","volume":"14","author":"AD Ciut\u0103","year":"2023","unstructured":"Ciut\u0103 AD, Nosol K, Kowal J, Mukherjee S, Ram\u00edrez AS, Stieger B, et al. Structure of human drug transporters OATP1B1 and OATP1B3. Nat Commun. 2023;14:5774.","journal-title":"Nat Commun"},{"key":"8105_CR142","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1080\/17425255.2022.2113380","volume":"18","author":"N Anabtawi","year":"2022","unstructured":"Anabtawi N, Drabison T, Hu S, Sparreboom A, Talebi Z. The role of OATP1B1 and OATP1B3 transporter polymorphisms in drug disposition and response to anticancer drugs: a review of the recent literature. Expert Opin Drug Metab Toxicol. 2022;18:459\u201368.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"8105_CR143","doi-asserted-by":"publisher","first-page":"604","DOI":"10.3892\/ol.2021.12865","volume":"22","author":"S Zhang","year":"2021","unstructured":"Zhang S, Xu J, Chen Q, Zhang F, Wang H, Guo H. lncRNA MT1JP-overexpression abolishes the silencing of PTEN by miR-32 in hepatocellular carcinoma. Oncol Lett. 2021;22:604.","journal-title":"Oncol Lett"},{"key":"8105_CR144","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1038\/s41392-020-00299-0","volume":"5","author":"T Zhou","year":"2020","unstructured":"Zhou T, Li S, Xiang D, Liu J, Sun W, Cui X, et al. m6A RNA methylation-mediated HNF3\u03b3 reduction renders hepatocellular carcinoma dedifferentiation and sorafenib resistance. Signal Transduct Target Ther. 2020;5:296.","journal-title":"Signal Transduct Target Ther"},{"key":"8105_CR145","doi-asserted-by":"publisher","first-page":"2783","DOI":"10.1016\/j.apsb.2021.01.001","volume":"11","author":"J Liu","year":"2021","unstructured":"Liu J, Ren L, Li S, Li W, Zheng X, Yang Y, et al. The biology, function, and applications of exosomes in cancer. Acta Pharm Sin B. 2021;11:2783\u201397.","journal-title":"Acta Pharm Sin B"},{"key":"8105_CR146","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/s41392-020-00261-0","volume":"5","author":"J Dai","year":"2020","unstructured":"Dai J, Su Y, Zhong S, Cong L, Liu B, Yang J, et al. Exosomes: key players in cancer and potential therapeutic strategy. Signal Transduct Target Ther. 2020;5:145.","journal-title":"Signal Transduct Target Ther"},{"key":"8105_CR147","doi-asserted-by":"publisher","first-page":"7908","DOI":"10.3390\/ijms24097908","volume":"24","author":"T Nakano","year":"2023","unstructured":"Nakano T, Chen CL, Chen IH, Tseng HP, Chiang KC, Lai CY, et al. Overexpression of miR-4669 enhances tumor aggressiveness and generates an immunosuppressive tumor microenvironment in hepatocellular carcinoma: its clinical value as a predictive biomarker. Int J Mol Sci. 2023;24:7908.","journal-title":"Int J Mol Sci"},{"key":"8105_CR148","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1007\/s13577-022-00800-7","volume":"36","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Pan Q, Shao Z. Extracellular vesicles derived from cancer-associated fibroblasts carry tumor-promotive microRNA-1228-3p to enhance the resistance of hepatocellular carcinoma cells to sorafenib. Hum Cell. 2023;36:296\u2013311.","journal-title":"Hum Cell"},{"key":"8105_CR149","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-022-02462-9","volume":"22","author":"Y Gao","year":"2022","unstructured":"Gao Y, Yin Z, Qi Y, Peng H, Ma W, Wang R, et al. Golgi phosphoprotein 3 promotes angiogenesis and sorafenib resistance in hepatocellular carcinoma via upregulating exosomal miR-494-3p. Cancer Cell Int. 2022;22:35.","journal-title":"Cancer Cell Int"},{"key":"8105_CR150","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-024-02582-6","volume":"22","author":"FL Dong","year":"2024","unstructured":"Dong FL, Xu ZZ, Wang YQ, Li T, Wang X, Li J. Exosome-derived circUPF2 enhances resistance to targeted therapy by redeploying ferroptosis sensitivity in hepatocellular carcinoma. J Nanobiotechnol. 2024;22:298.","journal-title":"J Nanobiotechnol"},{"key":"8105_CR151","doi-asserted-by":"publisher","DOI":"10.1002\/jbt.23666","volume":"38","author":"Y Bao","year":"2024","unstructured":"Bao Y, Xu S, Zhou J, Zhao C, Dai S, Zhang Y, et al. Exosomal miR-93 derived from hepatocellular carcinoma cell promotes the sorafenib resistance of hepatocellular carcinoma through PTEN\/PI3K\/Akt pathway. J Biochem Mol Toxicol. 2024;38:e23666.","journal-title":"J Biochem Mol Toxicol"},{"key":"8105_CR152","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","volume":"391","author":"M Kudo","year":"2018","unstructured":"Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391:1163\u201373.","journal-title":"Lancet"},{"key":"8105_CR153","doi-asserted-by":"publisher","first-page":"e484","DOI":"10.1002\/onco.13566","volume":"26","author":"A Nair","year":"2021","unstructured":"Nair A, Reece K, Donoghue MB, Yuan WV, Rodriguez L, Keegan P, et al. FDA supplemental approval summary: lenvatinib for the treatment of unresectable hepatocellular carcinoma. Oncologist. 2021;26:e484\u201391.","journal-title":"Oncologist"},{"key":"8105_CR154","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2020.188391","volume":"1874","author":"Y Zhao","year":"2020","unstructured":"Zhao Y, Zhang YN, Wang KT, Chen L. Lenvatinib for hepatocellular carcinoma: from preclinical mechanisms to anti-cancer therapy. Biochim Biophys Acta Rev Cancer. 2020;1874:188391.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"8105_CR155","doi-asserted-by":"publisher","first-page":"113","DOI":"10.2147\/JHC.S349369","volume":"9","author":"X Xu","year":"2022","unstructured":"Xu X, Jiang W, Han P, Zhang J, Tong L, Sun X. MicroRNA-128-3p mediates lenvatinib resistance of hepatocellular carcinoma cells by downregulating c-Met. J Hepatocell Carcinoma. 2022;9:113\u201326.","journal-title":"J Hepatocell Carcinoma"},{"key":"8105_CR156","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02030-x","volume":"23","author":"XY Zhang","year":"2024","unstructured":"Zhang XY, Li SS, Gu YR, Xiao LX, Ma XY, Chen XR, et al. CircPIAS1 promotes hepatocellular carcinoma progression by inhibiting ferroptosis via the miR-455-3p\/NUPR1\/FTH1 axis. Mol Cancer. 2024;23:113.","journal-title":"Mol Cancer"},{"key":"8105_CR157","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1007\/s12672-023-00673-8","volume":"14","author":"D Gu","year":"2023","unstructured":"Gu D, Tong M, Wang J, Zhang B, Liu J, Song G, et al. Overexpression of the lncRNA HOTAIRM1 promotes lenvatinib resistance by downregulating miR-34a and activating autophagy in hepatocellular carcinoma. Discov Oncol. 2023;14:66.","journal-title":"Discov Oncol"},{"key":"8105_CR158","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-04652-9","volume":"13","author":"T Han","year":"2022","unstructured":"Han T, Zheng H, Zhang J, Yang P, Li H, Cheng Z, et al. Downregulation of MUC15 by miR-183-5p.1 promotes liver tumor-initiating cells properties and tumorigenesis via regulating c-MET\/PI3K\/AKT\/SOX2 axis. Cell Death Dis. 2022;13:200.","journal-title":"Cell Death Dis"},{"key":"8105_CR159","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1093\/carcin\/bgac067","volume":"43","author":"Y Wei","year":"2022","unstructured":"Wei Y, Wei L, Han T, Ding S. miR-3154 promotes hepatocellular carcinoma progression via suppressing HNF4\u03b1. Carcinogenesis. 2022;43:1002\u201314.","journal-title":"Carcinogenesis"},{"key":"8105_CR160","doi-asserted-by":"publisher","first-page":"3678","DOI":"10.7150\/ijbs.85270","volume":"19","author":"M Cao","year":"2023","unstructured":"Cao M, Ren Y, Li Y, Deng J, Su X, Tang Y, et al. Lnc-ZEB2-19 inhibits the progression and lenvatinib resistance of hepatocellular carcinoma by attenuating the NF-\u03baB signaling pathway through the TRA2A\/RSPH14 axis. Int J Biol Sci. 2023;19:3678\u201393.","journal-title":"Int J Biol Sci"},{"key":"8105_CR161","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.2147\/JHC.S459633","volume":"11","author":"Y Feng","year":"2024","unstructured":"Feng Y, Liang L, Jia W, Wang J, Xu C, Zhu D, et al. Circ_0007386 promotes the progression of hepatocellular carcinoma through the miR-507\/ CCNT2 axis. J Hepatocell Carcinoma. 2024;11:1095\u2013112.","journal-title":"J Hepatocell Carcinoma"},{"key":"8105_CR162","doi-asserted-by":"publisher","unstructured":"Hu Y, Chen M, Sun S, Zhang C, Xin Z, Sun X, et al. Long non-coding RNA LINC01532 sustains redox homeostasis and accelerates lenvatinib resistance in hepatocellular carcinoma. J Adv Res. 2025. https:\/\/doi.org\/10.1016\/j.jare.2025.02.035.","DOI":"10.1016\/j.jare.2025.02.035"},{"key":"8105_CR163","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2025.217470","volume":"612","author":"L Yang","year":"2025","unstructured":"Yang L, Tan W, Wang M, Wei Y, Xie Z, Wang Q, et al. circCCNY enhances lenvatinib sensitivity and suppresses immune evasion in hepatocellular carcinoma by serving as a scaffold for SMURF1 mediated HSP60 degradation. Cancer Lett. 2025;612:217470.","journal-title":"Cancer Lett"},{"key":"8105_CR164","doi-asserted-by":"publisher","first-page":"394632025131669","DOI":"10.1177\/03946320251316692","volume":"39","author":"M Abudoureyimu","year":"2025","unstructured":"Abudoureyimu M, Sun N, Chen W, Lin X, Pan F, Wang R. Aurora-A promotes lenvatinib resistance experimentally through hsa-circ-0058046\/miR-424-5p\/FGFR1 axis in hepatocellular carcinoma. Int J Immunopathol Pharm. 2025;39:3946320251316692.","journal-title":"Int J Immunopathol Pharm"},{"key":"8105_CR165","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1053\/j.gastro.2023.01.041","volume":"164","author":"J Wang","year":"2023","unstructured":"Wang J, Yu H, Dong W, Zhang C, Hu M, Ma W, et al. N6-methyladenosine-mediated up-regulation of FZD10 regulates liver cancer stem cells\u2019 properties and lenvatinib resistance through WNT\/\u03b2-catenin and Hippo signaling pathways. Gastroenterology. 2023;164:990\u20131005.","journal-title":"Gastroenterology"},{"key":"8105_CR166","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41420-024-02282-y","volume":"11","author":"R Fang","year":"2025","unstructured":"Fang R, Jia Z, Xin Y, Zhao K, Qin W, Lu H, et al. N6-methyladenosine-modification of USP15 regulates chemotherapy resistance by inhibiting LGALS3 ubiquitin-mediated degradation via AKT\/mTOR signaling activation pathway in hepatocellular carcinoma. Cell Death Discov. 2025;11:3.","journal-title":"Cell Death Discov"},{"key":"8105_CR167","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1158\/0008-5472.CAN-22-0963","volume":"83","author":"M Huang","year":"2023","unstructured":"Huang M, Long J, Yao Z, Zhao Y, Zhao Y, Liao J, et al. METTL1-mediated m7G tRNA modification promotes lenvatinib resistance in hepatocellular carcinoma. Cancer Res. 2023;83:89\u2013102.","journal-title":"Cancer Res"},{"key":"8105_CR168","doi-asserted-by":"crossref","unstructured":"Wang M, Zou F, Wang S, Yang Y, Xia C, Chen L, et al. CRTC2 forms co-condensates with YTHDF2 that enhance translational efficiency of m6A-modified mRNAs to drive hepatocarcinogenesis and lenvatinib resistance. Cancer Res. 2025;85:2046\u201366.","DOI":"10.1158\/0008-5472.CAN-24-3196"},{"key":"8105_CR169","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.omtn.2021.06.022","volume":"26","author":"W Yang","year":"2021","unstructured":"Yang W, Li HY, Wu YF, Mi RJ, Liu WZ, Shen X, et al. ac4C acetylation of RUNX2 catalyzed by NAT10 spurs osteogenesis of BMSCs and prevents ovariectomy-induced bone loss. Mol Ther Nucleic Acids. 2021;26:135\u201347.","journal-title":"Mol Ther Nucleic Acids"},{"key":"8105_CR170","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-022-00964-7","volume":"20","author":"D Xu","year":"2022","unstructured":"Xu D, Liu Z, Liang MX, Fei YJ, Zhang W, Wu Y, et al. Endoplasmic reticulum stress targeted therapy for breast cancer. Cell Commun Signal. 2022;20:174.","journal-title":"Cell Commun Signal"},{"key":"8105_CR171","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s41420-023-01355-8","volume":"9","author":"Z Pan","year":"2023","unstructured":"Pan Z, Bao Y, Hu M, Zhu Y, Tan C, Fan L, et al. Role of NAT10-mediated ac4C-modified HSP90AA1 RNA acetylation in ER stress-mediated metastasis and lenvatinib resistance in hepatocellular carcinoma. Cell Death Discov. 2023;9:56.","journal-title":"Cell Death Discov"},{"key":"8105_CR172","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/4537343","volume":"2022","author":"A Duan","year":"2022","unstructured":"Duan A, Li H, Yu W, Zhang Y, Yin L. Long noncoding RNA XIST promotes resistance to lenvatinib in hepatocellular carcinoma cells via epigenetic inhibition of NOD2. J Oncol. 2022;2022:4537343.","journal-title":"J Oncol"},{"key":"8105_CR173","doi-asserted-by":"publisher","first-page":"9501","DOI":"10.3390\/ijms21249501","volume":"21","author":"J Wang","year":"2020","unstructured":"Wang J, Wang GG. No easy way out for EZH2: its pleiotropic, noncanonical effects on gene regulation and cellular function. Int J Mol Sci. 2020;21:9501.","journal-title":"Int J Mol Sci"},{"key":"8105_CR174","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202401399","volume":"11","author":"Y Lu","year":"2024","unstructured":"Lu Y, Zhu J, Zhang Y, Li W, Xiong Y, Fan Y, et al. Lactylation-driven IGF2BP3-mediated serine metabolism reprogramming and RNA m6A-modification promotes lenvatinib resistance in HCC. Adv Sci. 2024;11:e2401399.","journal-title":"Adv Sci"},{"key":"8105_CR175","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygeno.2025.110999","volume":"117","author":"F Yuan","year":"2025","unstructured":"Yuan F, Tang Y, Liang H, Cao M, Ren Y, Li Y, et al. CircPIK3C3 inhibits hepatocellular carcinoma progression and lenvatinib resistance by suppressing the Wnt\/\u03b2-catenin pathway via the miR-452-5p\/SOX15 axis. Genomics. 2025;117:110999.","journal-title":"Genomics"},{"key":"8105_CR176","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.3390\/cimb45020071","volume":"45","author":"H Tsuchiya","year":"2023","unstructured":"Tsuchiya H, Shinonaga R, Sakaguchi H, Kitagawa Y, Yoshida K. NEAT1-SOD2 axis confers sorafenib and lenvatinib resistance by activating AKT in liver cancer cell lines. Curr Issues Mol Biol. 2023;45:1073\u201385.","journal-title":"Curr Issues Mol Biol"},{"key":"8105_CR177","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2022.113335","volume":"420","author":"Y Wang","year":"2022","unstructured":"Wang Y, Tan K, Hu W, Hou Y, Yang G. LncRNA AC026401.3 interacts with OCT1 to intensify sorafenib and lenvatinib resistance by activating E2F2 signaling in hepatocellular carcinoma. Exp Cell Res. 2022;420:113335.","journal-title":"Exp Cell Res"},{"key":"8105_CR178","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1158\/0008-5472.CAN-23-1916","volume":"84","author":"X Zhang","year":"2024","unstructured":"Zhang X, Su T, Wu Y, Cai Y, Wang L, Liang C, et al. N6-methyladenosine reader YTHDF1 promotes stemness and therapeutic resistance in hepatocellular carcinoma by enhancing NOTCH1 expression. Cancer Res. 2024;84:827\u201340.","journal-title":"Cancer Res"},{"key":"8105_CR179","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.jhep.2020.11.008","volume":"74","author":"M Arechederra","year":"2021","unstructured":"Arechederra M, Bazai SK, Abdouni A, Sequera C, Mead TJ, Richelme S, et al. ADAMTSL5 is an epigenetically activated gene underlying tumorigenesis and drug resistance in hepatocellular carcinoma. J Hepatol. 2021;74:893\u2013906.","journal-title":"J Hepatol"},{"key":"8105_CR180","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41571-019-0267-4","volume":"17","author":"D Morel","year":"2020","unstructured":"Morel D, Jeffery D, Aspeslagh S, Almouzni G, Postel-Vinay S. Combining epigenetic drugs with other therapies for solid tumours - past lessons and future promise. Nat Rev Clin Oncol. 2020;17:91\u2013107.","journal-title":"Nat Rev Clin Oncol"},{"key":"8105_CR181","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/nm.4040","volume":"22","author":"AN Hata","year":"2016","unstructured":"Hata AN, Niederst MJ, Archibald HL, Gomez-Caraballo M, Siddiqui FM, Mulvey HE, et al. Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition. Nat Med. 2016;22:262\u20139.","journal-title":"Nat Med"},{"key":"8105_CR182","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.semcancer.2019.12.019","volume":"65","author":"S Gomez","year":"2020","unstructured":"Gomez S, Tabernacki T, Kobyra J, Roberts P, Chiappinelli KB. Combining epigenetic and immune therapy to overcome cancer resistance. Semin Cancer Biol. 2020;65:99\u2013113.","journal-title":"Semin Cancer Biol"},{"key":"8105_CR183","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1038\/s43018-021-00249-x","volume":"2","author":"MB Pappalardi","year":"2021","unstructured":"Pappalardi MB, Keenan K, Cockerill M, Kellner WA, Stowell A, Sherk C, et al. Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemia. Nat Cancer. 2021;2:1002\u201317.","journal-title":"Nat Cancer"},{"key":"8105_CR184","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s10555-025-10253-7","volume":"44","author":"A Suraweera","year":"2025","unstructured":"Suraweera A, O\u2019Byrne KJ, Richard DJ. Epigenetic drugs in cancer therapy. Cancer Metastasis Rev. 2025;44:37\u201361.","journal-title":"Cancer Metastasis Rev"},{"key":"8105_CR185","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2020.100167","volume":"2","author":"MG Fern\u00e1ndez-Barrena","year":"2020","unstructured":"Fern\u00e1ndez-Barrena MG, Arechederra M, Colyn L, Berasain C, Avila MA. Epigenetics in hepatocellular carcinoma development and therapy: the tip of the iceberg. JHEP Rep. 2020;2:100167.","journal-title":"JHEP Rep"},{"key":"8105_CR186","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.molonc.2012.09.003","volume":"6","author":"M New","year":"2012","unstructured":"New M, Olzscha H, La Thangue NB. HDAC inhibitor-based therapies: can we interpret the code?. Mol Oncol. 2012;6:637\u201356.","journal-title":"Mol Oncol"},{"key":"8105_CR187","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.jhep.2016.02.043","volume":"65","author":"M Bitzer","year":"2016","unstructured":"Bitzer M, Horger M, Giannini EG, Ganten TM, W\u00f6rns MA, Siveke JT, et al. Resminostat plus sorafenib as second-line therapy of advanced hepatocellular carcinoma\u2014the SHELTER study. J Hepatol. 2016;65:280\u20138.","journal-title":"J Hepatol"},{"key":"8105_CR188","doi-asserted-by":"publisher","first-page":"3046","DOI":"10.7150\/ijbs.93375","volume":"20","author":"S Yan","year":"2024","unstructured":"Yan S, Chen L, Zhuang H, Yang H, Yang Y, Zhang N, et al. HDAC inhibition sensitize hepatocellular carcinoma to lenvatinib via suppressing AKT activation. Int J Biol Sci. 2024;20:3046\u201360.","journal-title":"Int J Biol Sci"},{"key":"8105_CR189","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s13045-020-00937-8","volume":"13","author":"R Duan","year":"2020","unstructured":"Duan R, Du W, Guo W. EZH2: a novel target for cancer treatment. J Hematol Oncol. 2020;13:104.","journal-title":"J Hematol Oncol"},{"key":"8105_CR190","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2023.216122","volume":"559","author":"L Wang","year":"2023","unstructured":"Wang L, Yang Q, Zhou Q, Fang F, Lei K, Liu Z, et al. METTL3-m(6)A-EGFR-axis drives lenvatinib resistance in hepatocellular carcinoma. Cancer Lett. 2023;559:216122.","journal-title":"Cancer Lett"},{"key":"8105_CR191","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.chembiol.2023.12.009","volume":"31","author":"W Du","year":"2024","unstructured":"Du W, Huang Y, Chen X, Deng Y, Sun Y, Yang H, et al. Discovery of a PROTAC degrader for METTL3-METTL14 complex. Cell Chem Biol. 2024;31:177\u201383.e11.","journal-title":"Cell Chem Biol"},{"key":"8105_CR192","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2024.114389","volume":"444","author":"Y Liu","year":"2025","unstructured":"Liu Y, Chen M, Wang XX, Gao Y, Han X, Wang S, et al. Targeting METTL8 with Rabdosiin overcomes lenvatinib resistance in hepatocellular carcinoma. Exp Cell Res. 2025;444:114389.","journal-title":"Exp Cell Res"},{"key":"8105_CR193","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1021\/acs.jnatprod.4c00406","volume":"87","author":"L Zhao","year":"2024","unstructured":"Zhao L, Ma H, Jiang Y, Li Y, Qiao L, Chen Y, et al. Identification of an m6A natural inhibitor, Lobeline, that reverses lenvatinib resistance in hepatocellular tumors. J Nat Prod. 2024;87:1983\u201393.","journal-title":"J Nat Prod"},{"key":"8105_CR194","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s13287-023-03278-8","volume":"14","author":"S Zhou","year":"2023","unstructured":"Zhou S, Liu Y, Zhang Q, Xu H, Fang Y, Chen X, et al. Human menstrual blood-derived stem cells reverse sorafenib resistance in hepatocellular carcinoma cells through the hyperactivation of mitophagy. Stem Cell Res Ther. 2023;14:58.","journal-title":"Stem Cell Res Ther"},{"key":"8105_CR195","doi-asserted-by":"publisher","first-page":"3870","DOI":"10.3748\/wjg.v25.i29.3870","volume":"25","author":"E De Mattia","year":"2019","unstructured":"De Mattia E, Cecchin E, Guardascione M, Foltran L, Di Raimo T, Angelini F, et al. Pharmacogenetics of the systemic treatment in advanced hepatocellular carcinoma. World J Gastroenterol. 2019;25:3870\u201396.","journal-title":"World J Gastroenterol"},{"key":"8105_CR196","doi-asserted-by":"publisher","first-page":"709","DOI":"10.2174\/092986710790514462","volume":"17","author":"JJ Marin","year":"2010","unstructured":"Marin JJ, Romero MR, Briz O. Molecular bases of liver cancer refractoriness to pharmacological treatment. Curr Med Chem. 2010;17:709\u201340.","journal-title":"Curr Med Chem"},{"key":"8105_CR197","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2024.109821","volume":"27","author":"R Zhang","year":"2024","unstructured":"Zhang R, Dai J, Yao F, Zhou S, Huang W, Xu J, et al. Hypomethylation-enhanced CRTC2 expression drives malignant phenotypes and primary resistance to immunotherapy in hepatocellular carcinoma. iScience. 2024;27:109821.","journal-title":"iScience"},{"key":"8105_CR198","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.ccell.2020.03.007","volume":"37","author":"A Marusyk","year":"2020","unstructured":"Marusyk A, Janiszewska M, Polyak K. Intratumor heterogeneity: the Rosetta Stone of therapy resistance. Cancer Cell. 2020;37:471\u201384.","journal-title":"Cancer Cell"},{"key":"8105_CR199","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.2147\/JHC.S476439","volume":"11","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Lei J, Ma H, Zuo S. Impact of type of lenvatinib resistance on prognosis and second-line regimen in patients with virus-associated HCC. J Hepatocell Carcinoma. 2024;11:1507\u201317.","journal-title":"J Hepatocell Carcinoma"},{"key":"8105_CR200","doi-asserted-by":"publisher","first-page":"4420","DOI":"10.1158\/1078-0432.CCR-03-0732","volume":"10","author":"G Gifford","year":"2004","unstructured":"Gifford G, Paul J, Vasey PA, Kaye SB, Brown R. The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients. Clin Cancer Res. 2004;10:4420\u20136.","journal-title":"Clin Cancer Res"},{"key":"8105_CR201","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1038\/s41586-021-03994-2","volume":"598","author":"SM Zhang","year":"2021","unstructured":"Zhang SM, Cai WL, Liu X, Thakral D, Luo J, Chan LH, et al. KDM5B promotes immune evasion by recruiting SETDB1 to silence retroelements. Nature. 2021;598:682\u20137.","journal-title":"Nature"},{"key":"8105_CR202","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1080\/15592294.2018.1436364","volume":"13","author":"O Vera","year":"2018","unstructured":"Vera O, Rodriguez-Antolin C, de Castro J, Karreth FA, Sellers TA, Ibanez de Caceres I. An epigenomic approach to identifying differential overlapping and cis-acting lncRNAs in cisplatin-resistant cancer cells. Epigenetics. 2018;13:251\u201363.","journal-title":"Epigenetics"},{"key":"8105_CR203","doi-asserted-by":"publisher","DOI":"10.1177\/17588359241299678","volume":"17","author":"J Lei","year":"2025","unstructured":"Lei J, Dai H, Zhang Y, Ou G, Peng Liang Z, Lu Y, et al. Prognostic impact of primary versus secondary resistance to sorafenib in patients with HCC. Ther Adv Med Oncol. 2025;17:17588359241299678.","journal-title":"Ther Adv Med Oncol"},{"key":"8105_CR204","doi-asserted-by":"publisher","first-page":"2981","DOI":"10.2147\/OTT.S192572","volume":"12","author":"A Casadei Gardini","year":"2019","unstructured":"Casadei Gardini A, Puzzoni M, Montagnani F, Marisi G, Tamburini E, Cucchetti A, et al. Profile of lenvatinib in the treatment of hepatocellular carcinoma: design, development, potential place in therapy and network meta-analysis of hepatitis B and hepatitis C in all Phase III trials. Onco Targets Ther. 2019;12:2981\u20138.","journal-title":"Onco Targets Ther"},{"key":"8105_CR205","doi-asserted-by":"publisher","first-page":"4305","DOI":"10.2147\/OTT.S312748","volume":"14","author":"S De Matteis","year":"2021","unstructured":"De Matteis S, Ghetti M, Gramantieri L, Marisi G, Casadei-Gardini A. Sorafenib in the treatment of virus-related HCC: differences between HCV and HBV. Onco Targets Ther. 2021;14:4305\u20138.","journal-title":"Onco Targets Ther"},{"key":"8105_CR206","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.canlet.2014.07.004","volume":"352","author":"K Mao","year":"2014","unstructured":"Mao K, Zhang J, He C, Xu K, Liu J, Sun J, et al. Restoration of miR-193b sensitizes Hepatitis B virus-associated hepatocellular carcinoma to sorafenib. Cancer Lett. 2014;352:245\u201352.","journal-title":"Cancer Lett"},{"key":"8105_CR207","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1158\/1078-0432.CCR-09-2123","volume":"16","author":"C Braconi","year":"2010","unstructured":"Braconi C, Valeri N, Gasparini P, Huang N, Taccioli C, Nuovo G, et al. Hepatitis C virus proteins modulate microRNA expression and chemosensitivity in malignant hepatocytes. Clin Cancer Res. 2010;16:957\u201366.","journal-title":"Clin Cancer Res"},{"key":"8105_CR208","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jhep.2008.10.019","volume":"50","author":"DL Zheng","year":"2009","unstructured":"Zheng DL, Zhang L, Cheng N, Xu X, Deng Q, Teng XM, et al. Epigenetic modification induced by hepatitis B virus X protein via interaction with de novo DNA methyltransferase DNMT3A. J Hepatol. 2009;50:377\u201387.","journal-title":"J Hepatol"},{"key":"8105_CR209","doi-asserted-by":"publisher","DOI":"10.1038\/emm.2016.177","volume":"49","author":"B Zhang","year":"2017","unstructured":"Zhang B, Han S, Feng B, Chu X, Chen L, Wang R. Hepatitis B virus X protein-mediated non-coding RNA aberrations in the development of human hepatocellular carcinoma. Exp Mol Med. 2017;49:e293.","journal-title":"Exp Mol Med"},{"key":"8105_CR210","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/s41575-020-00381-6","volume":"18","author":"DQ Huang","year":"2021","unstructured":"Huang DQ, El-Serag HB, Loomba R. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2021;18:223\u201338.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"8105_CR211","doi-asserted-by":"publisher","DOI":"10.1177\/17562848221100106","volume":"15","author":"J Howell","year":"2022","unstructured":"Howell J, Samani A, Mannan B, Hajiev S, Motedayen Aval L, Abdelmalak R, et al. Impact of NAFLD on clinical outcomes in hepatocellular carcinoma treated with sorafenib: an international cohort study. Ther Adv Gastroenterol. 2022;15:17562848221100106.","journal-title":"Ther Adv Gastroenterol"},{"key":"8105_CR212","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1016\/j.cgh.2021.11.020","volume":"21","author":"AG Singal","year":"2023","unstructured":"Singal AG, Nagar SP, Hitchens A, Davis KL, Iyer S. Real-world effectiveness of lenvatinib in hepatocellular carcinoma patients with nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol. 2023;21:830\u20131.e1.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"8105_CR213","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1002\/jgh3.12663","volume":"5","author":"T Tomonari","year":"2021","unstructured":"Tomonari T, Sato Y, Tanaka H, Mitsuhashi T, Hirao A, Tanaka T, et al. Therapeutic efficacy of lenvatinib in nonviral unresectable hepatocellular carcinoma. JGH Open. 2021;5:1275\u201383.","journal-title":"JGH Open"},{"key":"8105_CR214","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-55932-7","volume":"14","author":"X Wu","year":"2024","unstructured":"Wu X, Zeng M, Wei Y, Lu R, Huang Z, Huang L, et al. METTL3 and METTL14-mediated N(6)-methyladenosine modification of SREBF2-AS1 facilitates hepatocellular carcinoma progression and sorafenib resistance through DNA demethylation of SREBF2. Sci Rep. 2024;14:6155.","journal-title":"Sci Rep"},{"key":"8105_CR215","doi-asserted-by":"crossref","unstructured":"Arif KMT, Elliott EK, Haupt LM, Griffiths LR. Regulatory mechanisms of epigenetic miRNA relationships in human cancer and potential as therapeutic targets. Cancers. 2020;12:2922.","DOI":"10.3390\/cancers12102922"},{"key":"8105_CR216","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-019-1075-2","volume":"18","author":"LQ Cao","year":"2019","unstructured":"Cao LQ, Yang XW, Chen YB, Zhang DW, Jiang XF, Xue P. Exosomal miR-21 regulates the TETs\/PTENp1\/PTEN pathway to promote hepatocellular carcinoma growth. Mol Cancer. 2019;18:148.","journal-title":"Mol Cancer"},{"key":"8105_CR217","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2022.215899","volume":"548","author":"L Zhang","year":"2022","unstructured":"Zhang L, Li HT, Shereda R, Lu Q, Weisenberger DJ, O\u2019Connell C, et al. DNMT and EZH2 inhibitors synergize to activate therapeutic targets in hepatocellular carcinoma. Cancer Lett. 2022;548:215899.","journal-title":"Cancer Lett"},{"key":"8105_CR218","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1080\/17425255.2017.1260546","volume":"13","author":"A Majchrzak-Celi\u0144ska","year":"2017","unstructured":"Majchrzak-Celi\u0144ska A, Baer-Dubowska W. Pharmacoepigenetics: an element of personalized therapy?. Expert Opin Drug Metab Toxicol. 2017;13:387\u201398.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"8105_CR219","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1111\/cge.12362","volume":"86","author":"S Sethi","year":"2014","unstructured":"Sethi S, Ali S, Sethi S, Sarkar FH. MicroRNAs in personalized cancer therapy. Clin Genet. 2014;86:68\u201373.","journal-title":"Clin Genet"},{"key":"8105_CR220","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1111\/bph.17413","volume":"182","author":"C Tang","year":"2025","unstructured":"Tang C, Tang C, Zhu X, Wang S, Yang Y, Miao Y, et al. Loss of AXIN1 regulates response to lenvatinib through a WNT\/KDM5B\/p15 signalling axis in hepatocellular carcinoma. Br J Pharm. 2025;182:1394\u2013409.","journal-title":"Br J Pharm"},{"key":"8105_CR221","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2020.112760","volume":"208","author":"YD Fu","year":"2020","unstructured":"Fu YD, Huang MJ, Guo JW, You YZ, Liu HM, Huang LH, et al. Targeting histone demethylase KDM5B for cancer treatment. Eur J Med Chem. 2020;208:112760.","journal-title":"Eur J Med Chem"},{"key":"8105_CR222","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.canlet.2017.03.038","volume":"398","author":"M Huang","year":"2017","unstructured":"Huang M, Chen C, Geng J, Han D, Wang T, Xie T, et al. Targeting KDM1A attenuates Wnt\/\u03b2-catenin signaling pathway to eliminate sorafenib-resistant stem-like cells in hepatocellular carcinoma. Cancer Lett. 2017;398:12\u201321.","journal-title":"Cancer Lett"},{"key":"8105_CR223","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s13045-019-0811-9","volume":"12","author":"Y Fang","year":"2019","unstructured":"Fang Y, Liao G, Yu B. LSD1\/KDM1A inhibitors in clinical trials: advances and prospects. J Hematol Oncol. 2019;12:129.","journal-title":"J Hematol Oncol"},{"key":"8105_CR224","doi-asserted-by":"publisher","first-page":"20230037","DOI":"10.1002\/EXP.20230037","volume":"4","author":"Z Cao","year":"2024","unstructured":"Cao Z, Liu J, Yang X. Deformable nanocarriers for enhanced drug delivery and cancer therapy. Exploration. 2024;4:20230037.","journal-title":"Exploration"},{"key":"8105_CR225","doi-asserted-by":"publisher","DOI":"10.1016\/j.ntm.2025.100076","volume":"4","author":"EE Elemike","year":"2025","unstructured":"Elemike EE, Onunkwo IC, Ughumiakpor O, Alawuru F, Mukoro A, Ishom P, et al. Bio-nanomaterials: Promising anticancer properties and treatment strategies. Nano Transmed. 2025;4:100076.","journal-title":"Nano Transmed"},{"key":"8105_CR226","doi-asserted-by":"publisher","DOI":"10.1016\/j.ntm.2023.100023","volume":"2","author":"C Lei","year":"2023","unstructured":"Lei C. Nanotechnology: Paving the way for advanced healthcare and beyond. Nano Transmed. 2023;2:100023.","journal-title":"Nano Transmed"},{"key":"8105_CR227","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1166\/jbn.2021.3033","volume":"17","author":"S Zhou","year":"2021","unstructured":"Zhou S, Ma Y, Liu X, Yu P, Huang N, Song L, et al. Targeted delivery of glypican 3 (GPC3) antibody-modified microRNA (miR let-7b-5p) polymer nanoparticles to sorafenib-resistant hepatocellular carcinoma cells. J Biomed Nanotechnol. 2021;17:677\u201390.","journal-title":"J Biomed Nanotechnol"},{"key":"8105_CR228","doi-asserted-by":"publisher","first-page":"3965","DOI":"10.2147\/DDDT.S332847","volume":"15","author":"GN He","year":"2021","unstructured":"He GN, Bao NR, Wang S, Xi M, Zhang TH, Chen FS. Ketamine induces ferroptosis of liver cancer cells by targeting lncRNA PVT1\/miR-214-3p\/GPX4. Drug Des Dev Ther. 2021;15:3965\u201378.","journal-title":"Drug Des Dev Ther"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08105-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08105-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08105-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T18:02:12Z","timestamp":1764612132000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08105-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,26]]},"references-count":228,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["8105"],"URL":"https:\/\/doi.org\/10.1038\/s41419-025-08105-x","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,26]]},"assertion":[{"value":"20 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"875"}}